Cytek BioSciences Inc Dossier
Qualitative Analysis
Business overview
Cytek Biosciences, Inc. (NASDAQ: CTKB) is a leading life sciences technology company specializing in high-resolution, high-content, and high-sensitivity cell analysis solutions. The company is renowned for its patented Full Spectrum Profiling™ (FSP™) technology, which captures fluorescent signals across the entire spectrum to enable advanced multiplexing. Cytek's comprehensive product portfolio includes its core FSP instruments (such as the Aurora, Northern Lights, Aurora CS, and the newly launched Aurora Evo systems), reagents, software, and global services. Following its 2023 acquisition of the Amnis and Guava flow cytometry businesses, Cytek has expanded its reach into imaging flow cytometry and benchtop cell analysis, serving academic, biopharmaceutical, and clinical research organizations globally.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Refocusing operations into three distinct business units: (1) Solutions and Clinical (including reagents, Guava, Muse Micro, and Northern Lights), (2) Research Technology (focusing on high-parameter flow cytometry in the research-use-only market), and (3) Service (supporting the installed base across both groups).
Expected impact: Aims to enhance market alignment, accelerate commercial execution, and capture high-growth clinical and reagent opportunities.
Operationalizing and scaling the new manufacturing facility in Singapore to complement existing operations in the U.S. and China.
Expected impact: Provides meaningful mitigation against tariff-related cost pressures, optimizes regional supply chains, and ensures continuity of supply for APAC and global customers.
Driving reagent sales and customer engagement by leveraging the Cytek Cloud digital ecosystem, which surpassed 26,000 users as of Q1 2026, and utilizing intelligent panel design tools like SpectroPanel.
Expected impact: Accelerates high-margin recurring consumable revenue by simplifying complex panel design workflows for researchers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the Flow Cytometry & Imaging (FCI) business unit from DiaSorin subsidiary Luminex, adding the Amnis imaging flow cytometry and Guava microcapillary flow cytometry product lines.
Financial impact: Contributed immediate revenue in 2023 and helped drive dramatic improvements in service segment gross margins (reaching 57% by 2024).
Immaterial asset acquisition to expand local service, support, and distribution capabilities.
Financial impact: Immaterial impact on overall financials; increased goodwill and customer relationship intangible assets.
Strategic Partnerships
Enables Cytek to access Bio-Rad's StarBright Dyes to develop, manufacture, and commercialize high-parameter reagent products optimized for Cytek's Full Spectrum Profiling (FSP) flow cytometry systems.
Terms: Financial terms were not publicly disclosed.
Cytek provides state-of-the-art spectral cytometry platforms and trained support personnel to the joint CRG-UPF Flow Cytometry Unit in Barcelona to develop and test new methodologies, driving technological innovation and expanding FSP applications.
Terms: Cytek provides instruments and support personnel; specific financial terms were not disclosed.